Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

700
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
700
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.2K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

418
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
418
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.2K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.2K
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

931
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
931

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults with Depression and Mild Cognitive Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Can Psychedelics Help Us Reimagine Prevention of Posttraumatic Stress Disorder?

Biological psychiatry·2026
Same author

Role of the Locus Coeruleus in Response to Threat in Anxiety Disorders and Posttraumatic Stress Disorder: An Ultra-High-Field 7T Functional Magnetic Resonance Imaging Study.

Biological psychiatry global open science·2025
Same author

Factors Influencing Perceived Mental Health Service Needs, Self-reported Utilization, and Barriers to Care Among Health System Faculty and Staff.

Journal of occupational and environmental medicine·2025
Same author

Association of Psychological Resilience With Decelerated Brain Aging in Cognitively Healthy World Trade Center Responders.

Biological psychiatry global open science·2025
Same author

Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.

The Journal of clinical psychiatry·2025

Related Experiment Video

Updated: Dec 25, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K

A New Rapid-Acting Antidepressant.

John H Krystal1, Dennis S Charney1, Ronald S Duman1

  • 1Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT 06511, USA.

Cell
|April 4, 2020
PubMed
Summary
This summary is machine-generated.

The discovery of rapid antidepressant effects from r/s-ketamine offers new biological insights. This led to FDA approval of Esketamine (Spravato), a novel depression treatment.

More Related Videos

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

454

Related Experiment Videos

Last Updated: Dec 25, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.6K
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.2K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

454

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Treatment-resistant depression (TRD) remains a significant clinical challenge.
  • Existing antidepressant therapies have limitations in efficacy and speed of action.
  • The biological mechanisms underlying depression are not fully understood.

Purpose of the Study:

  • To highlight the discovery of rapid antidepressant effects of r/s-ketamine.
  • To discuss the implications for understanding antidepressant biology.
  • To report the FDA approval of Esketamine (Spravato) for depression.

Main Methods:

  • Review of preclinical and clinical studies on ketamine's antidepressant effects.
  • Analysis of the pharmacological properties of ketamine and its isomers.
  • Examination of the regulatory pathway leading to Esketamine approval.

Main Results:

  • r/s-ketamine demonstrates rapid and robust antidepressant effects in patients with TRD.
  • These findings have provided novel insights into the neurobiology of depression and antidepressant action.
  • Esketamine (Spravato), the S-isomer of ketamine, received FDA approval.

Conclusions:

  • Ketamine represents a mechanistically novel therapeutic approach for depression.
  • Esketamine (Spravato) offers a new treatment option for individuals with antidepressant-resistant depression.
  • Further research into ketamine's mechanisms may yield additional therapeutic strategies.